NCT03127215: Study of Olaparib/Trabectedin vs. Doctor’s Choice in Solid Tumors

NCT03127215
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: BRCA+, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have tumor with DNA repair deficiency including but not limited to the following genes: ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1, BRCA2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC
Exclusions: 
https://ClinicalTrials.gov/show/NCT03127215

Comments are closed.

Up ↑